AKT-IN-27
AKT-IN-27 (4a) is a potential anticancer agent through selective therapeutic targeting of Akt-driven pathways. AKT-IN-27 (4a) induces apoptosis via caspase-3 activation, G2/M cell cycle arrest, and mitochondrial membrane potential disruption. AKT-IN-27 (4a) can be used in the research for TNBC (triple-negative breast cancer) [1].
Product Specifications
UNSPSC
12352211
Target
Akt; Apoptosis
Related Pathways
Apoptosis; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(C1=C(NC2=CC=CC=C2)SC(C3=O)=C1C(C4=C3C=CC=C4)=O)OCC
Molecular Formula
C21H15NO4S
Molecular Weight
377.41
References & Citations
[1]Soumen K. Manik, et al., Design, synthesis, and in vitro and in vivo biological evaluation of 2-amino-naphtho[2,3-b]thiophene-4,9-dione derivatives as potent anticancer agents. European Journal of Medicinal Chemistry. 8 May 2025.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
